[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"customer-session":3,"post:glp3-rt-vs-tirzepatide-vs-semaglutide-mechanism-and-research-comparison":5},{"loggedIn":4},false,{"id":6,"slug":7,"title":8,"content":9,"excerpt":10,"path":11,"modified":12,"featuredImage":13,"seo":17,"date":20,"author":21,"categories":22,"readingMinutes":29},41719,"glp3-rt-vs-tirzepatide-vs-semaglutide-mechanism-and-research-comparison","Glp3-Rt vs Tirzepatide vs Semaglutide: Mechanism and Research Comparison","\u003Cp>\u003Cspan style=\"font-weight: 400;\">By \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fauthor\u002Fclarkjones\u002F\">\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, Velora Research \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297)). Last reviewed 2026-05-28.\u003C\u002Fspan>\u003C\u002Fi>\u003C\u002Fp>\n\u003Cp>\u003Cb>Quick answer:\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> Semaglutide, tirzepatide, and Glp3-Rt are three peptides that look related on a slide yet differ substantially in the receptors they activate. The simplest way to keep them straight is by counting receptors: semaglutide acts on one (GLP-1), tirzepatide on two (GLP-1 and GIP), and Glp3-Rt on three (GLP-1, GIP, and glucagon). The first two are FDA-approved drugs sold by prescription. The third is investigational, and Velora supplies it strictly for in-vitro research as GLP-3 RT.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Research use only: what this article is, and what it isn’t\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">This article is a mechanism-focused literature comparison written for researchers selecting a metabolic peptide for in-vitro or preclinical work. It is not medical advice. It is not a prescribing guide, a self-administration guide, or a recommendation for any human use.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are FDA-approved prescription medications, available only from licensed providers for their labeled indications. Glp3-Rt is investigational and not approved by the FDA, EMA, or any other regulator for any indication. The Glp3-Rt research compound Velora supplies as GLP-3 RT is sold strictly for laboratory research use, not for human consumption, veterinary use, or in vivo use in any species.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Researchers handling any of these compounds are responsible for compliance with applicable law and institutional review requirements, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3). The clinical-trial figures cited below are reported for context only. They are not a research dosing protocol.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>The receptor question, in one paragraph\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The primary pharmacological differences between these peptides arise from the receptor they activate, although molecular structure and pharmacokinetic properties also contribute. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are the two main incretin hormones your gut releases after a meal; both raise insulin in a glucose-dependent way. Glucagon primarily promotes hepatic glucose production and mobilization of energy stores during fasting. Putting agonist activity at all three receptors into a single molecule is a relatively new pharmacology, and Glp3-Rt is the lead compound exploring it.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cb>Compound\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Investigator\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Receptor activity\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Half-life\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>FDA status\u003C\u002Fb>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Semaglutide\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Novo Nordisk\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">GLP-1R agonist\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~165 hours (~1 week)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Approved (Ozempic, Wegovy)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Tirzepatide\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Eli Lilly\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">GLP-1R + GIPR dual agonist\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~120 hours (~5 days)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Approved (Mounjaro, Zepbound)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Glp3-Rt\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Eli Lilly\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">GLP-1R + GIPR + GCGR triple agonist\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~6 days (preliminary, Phase 2)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Investigational, not approved\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Half-life values for the approved compounds come from prescribing information; Glp3-Rt values are from the published Phase 2 work and may be refined as Phase 3 data accumulates.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Semaglutide, in research terms\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Semaglutide is the most extensively studied of the three. It is a GLP-1 receptor agonist with structural modifications, including a fatty-acid side chain, that extend its half-life enough to support once-weekly dosing. In the STEP-1 trial published in \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">The New England Journal of Medicine\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\"> in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2032183\">\u003Cspan style=\"font-weight: 400;\">Wilding et al., NEJM, 2021\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). On the cardiovascular side, the SUSTAIN-6 trial in 2016 was one of the first to report a significant reduction in major adverse cardiovascular events with semaglutide in adults with type 2 diabetes and high cardiovascular risk (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa1607141\">\u003Cspan style=\"font-weight: 400;\">Marso et al., NEJM, 2016\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). For benchwork, semaglutide is the reference agonist when you want to study GLP-1 receptor pharmacology in isolation.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Tirzepatide, in research terms\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Tirzepatide adds a second receptor. It is a single molecule with balanced agonist activity at both the GLP-1 receptor and the GIP receptor, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. In SURMOUNT-1, published in \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\"> in 2022, tirzepatide at the 15 mg weekly dose produced a mean placebo-adjusted body weight reduction of 17.8% at 72 weeks in adults with obesity (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2206038\">\u003Cspan style=\"font-weight: 400;\">Jastreboff et al., NEJM, 2022\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). The SURPASS program established efficacy in type 2 diabetes across multiple comparators, including head-to-head superiority versus semaglutide on HbA1c reduction in SURPASS-2 (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2107519\">\u003Cspan style=\"font-weight: 400;\">Frías et al., NEJM, 2021\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">).\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">For research use, tirzepatide is the comparator most often used to ask the question, “what does adding GIP activity contribute beyond what GLP-1 alone provides?” That question is still actively being answered. The proposed mechanism most often cited involves GIP-receptor-mediated effects on adipose insulin sensitivity and possibly on central energy balance, though attribution between the two receptors in vivo remains an area of ongoing study.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Glp3-Rt, in research terms\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Glp3-Rt, originally designated LY3437943 by Eli Lilly, is the first triple agonist to reach late-stage clinical evaluation. It functions as an agonist at the GLP-1, GIP, and glucagon receptors with activity across all three targets. In the Phase 2 obesity trial published in \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\"> in 2023, Glp3-Rt at the 12 mg weekly dose produced a mean placebo-adjusted body weight reduction of 22.1 percentage points (22.1% (24.2% arm) mean absolute reduction on the Glp3-Rt arm) at 48 weeks (\u003C\u002Fspan>\u003Cspan style=\"font-weight: 400;\">Jastreboff et al., NEJM, 2023\u003C\u002Fspan>\u003Cspan style=\"font-weight: 400;\">). The Phase 2a MASLD readout published in \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Nature Medicine\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\"> in 2024 reported dose-dependent reductions in liver fat content across the same dose range (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2\">\u003Cspan style=\"font-weight: 400;\">Sanyal et al., Nature Medicine, 2024\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">).\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The glucagon-receptor activity is the part that makes Glp3-Rt pharmacologically distinct. In preclinical models, glucagon agonism has been associated with increased energy expenditure and hepatic lipid mobilization. The MASH mouse and hamster work published by Briand and colleagues in 2026 showed dose-dependent reductions in body weight, hepatic steatosis, and liver enzymes that exceeded what dual agonists produced in the same models (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Foby.70155?af=R\">\u003Cspan style=\"font-weight: 400;\">Briand et al., Obesity, 2026\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). “Proposed mechanism” is still the honest framing for that observation, because the in vivo contribution of glucagon-receptor agonism in humans is what the Phase 3 program is currently characterizing.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>A side-by-side reference table\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">This table is for orientation, not protocol design. It summarizes what published research has reported at the most-studied weekly dose for each compound.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cspan style=\"font-weight: 400;\">****\u003C\u002Fspan>\u003C\u002Fth>\n\u003Cth>\u003Cb>Semaglutide (STEP-1)\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Tirzepatide (SURMOUNT-1)\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Glp3-Rt (Phase 2)\u003C\u002Fb>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Trial population\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Adults with overweight or obesity\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Adults with obesity\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Adults with obesity\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Dose studied\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.4 mg\u002Fwk\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">15 mg\u002Fwk\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">12 mg\u002Fwk\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Trial duration\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">68 weeks\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">72 weeks\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">48 weeks\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Placebo-adjusted weight reduction\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">12.4%\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">17.8%\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">24.2%\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Receptor count\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">1 (GLP-1)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2 (GLP-1, GIP)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">3 (GLP-1, GIP, GCGR)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Reference\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Wilding et al., NEJM 2021\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Jastreboff et al., NEJM 2022\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Jastreboff et al., NEJM 2023\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">A note on what this table is not telling you. These trials enrolled different populations under different protocols, so the percentages are not a head-to-head ranking. The numbers are comparable in direction, not in scientific equivalence. For an actual head-to-head, the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06662383\">\u003Cspan style=\"font-weight: 400;\">TRIUMPH-5 trial\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> is currently comparing Glp3-Rt directly against tirzepatide, with primary completion expected in late 2026.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>What you are actually choosing between in the lab\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">If your research question is GLP-1 receptor pharmacology in isolation, semaglutide is the deepest-validated reference agonist. If you are asking what GIP receptor co-activation contributes, tirzepatide is the comparator that the literature has built around. If you are investigating triple-receptor pharmacology in metabolic, hepatic, or cardiometabolic models, Glp3-Rt is the lead compound and the one Velora supplies as GLP-3 RT.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The other variable that matters in benchwork is what you can actually trust about the material. Two vials labeled “Glp3-Rt” from two vendors are not interchangeable if one ships without a current third-party Certificate of Analysis. Identity confirmation by mass spectrometry, purity quantification by HPLC, and confirmation of low bacterial endotoxin are not optional steps for material that is going to inform published data.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">“I have read enough COAs to know that the difference between a useful peptide and a noisy assay often shows up before you ever reconstitute. If the HPLC trace has unidentified peaks, or the mass spec doesn’t confirm the parent ion at the expected m\u002Fz, downstream experimental precision cannot compensate for poor starting material.”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD, Velora Research\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Velora Research provides a third-party Certificate of Analysis for every product in the catalog, including \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fglp-3-rt\u002F\">\u003Cspan style=\"font-weight: 400;\">GLP-3 RT, our Glp3-Rt research compound\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">. Each COA is batch-specific and traceable: identity by mass spec, purity (≥99%) by HPLC, water content by Karl Fischer, endotoxin by LAL. The same release protocol applies across the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">\u003Cspan style=\"font-weight: 400;\">research peptide catalog\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, and the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">\u003Cspan style=\"font-weight: 400;\">quality and testing process\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> is documented end to end. For published or grant-funded research, that batch-level documentation is what lets your methods section stand up to peer review.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Frequently asked questions\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cb>Is Glp3-Rt stronger than tirzepatide?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> That is a comparison the existing literature cannot answer directly. The percentages from the Phase 2 Glp3-Rt trial and the Phase 3 tirzepatide trials look different, but those trials enrolled different populations under different protocols. The TRIUMPH-5 head-to-head trial between Glp3-Rt and tirzepatide is currently ongoing, with primary completion expected in late 2026; that readout will be the first true comparison.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>What does “GLP-3” mean?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> “GLP-3” is informal shorthand used in catalogs and some literature for triple agonists of the GLP-1, GIP, and glucagon receptors. It is not a formal pharmacological classification. Glp3-Rt is the lead compound the term is associated with.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Are semaglutide and tirzepatide available for research purchase the way Glp3-Rt is?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> Semaglutide and tirzepatide are FDA-approved prescription drugs, manufactured and distributed under controlled supply chains for clinical use. Velora supplies research-grade peptides for in-vitro work and does not sell reference standards of approved drugs.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Why does Glp3-Rt get described as having “balanced” agonist activity?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> Because the published Phase 2 pharmacology characterizes it as having comparable potency at all three receptors rather than being a single-receptor compound with weak off-target activity. That balance is what distinguishes it from earlier triple-agonist molecules with skewed receptor preference.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>What is the most useful next read after this article?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> For the dosing-math side of working with Glp3-Rt as a research compound, our \u003C\u002Fspan>\u003Ca href=\"about:blank\">\u003Cspan style=\"font-weight: 400;\">Glp3-Rt dosage chart and reconstitution reference\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> covers the same molecule from the bench side: reconstitution math, molar concentrations, storage windows, and the human-trial doses laid out as a reference-only table.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Sources and further reading\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cul>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2021. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2032183\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2016. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa1607141\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2022. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2206038\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2021. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2107519\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Glp3-Rt for Obesity: A Phase 2 Trial. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">NEJM\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2023. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Sanyal AJ, et al. Triple hormone receptor agonist Glp3-Rt for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Nature Medicine\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2024. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Briand F, et al. Glp3-Rt Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Obesity\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2026. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Foby.70155?af=R\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">ClinicalTrials.gov, NCT06662383, TRIUMPH-5 (Glp3-Rt vs tirzepatide head-to-head). \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06662383\">\u003Cspan style=\"font-weight: 400;\">Trial page\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n","By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297)). Last reviewed 2026-05-28.…","\u002Fblogs\u002Fglp3-rt-vs-tirzepatide-vs-semaglutide-mechanism-and-research-comparison","2026-08-12T18:38:32",{"src":14,"alt":8,"width":15,"height":16},"https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002FRetatrutide-vs-Tirzepatide-vs-Semaglutide-Mechanism-and-Research-Comparison.jpeg",1376,768,{"title":8,"description":18,"canonical":19,"ogTitle":8,"ogDescription":18,"ogImage":14,"robots":19},"By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-000…",null,"2026-07-14T17:24:16","Clark Jones",[23,26],{"name":24,"slug":25},"Blogs","blogs",{"name":27,"slug":28},"Research & Education","research-education",8]